Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to show a fall in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025
The Bridgewater New Jersey-based company is expected to report a 24.2% decrease in revenue to $150 thousand from $198 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vyne Therapeutics Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vyne Therapeutics Inc is $4.50, about 91.6% above its last closing price of $0.38
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.29 | -0.29 | -0.20 | Beat | 31 |
Dec. 31 2025 | -0.30 | -0.30 | -0.28 | Beat | 7.7 |
Sep. 30 2024 | -0.23 | -0.23 | -0.29 | Missed | -23.4 |
Jun. 30 2024 | -0.19 | -0.19 | -0.22 | Missed | -15.8 |
Mar. 31 2024 | -0.24 | -0.24 | -0.15 | Beat | 37.5 |
Dec. 31 2023 | -0.50 | -0.50 | -0.20 | Beat | 60 |
Sep. 30 2023 | -0.76 | -0.76 | -2.01 | Missed | -164.5 |
Jun. 30 2023 | -1.99 | -1.99 | -3.09 | Missed | -55.3 |
This summary was machine generated August 8 at 15:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)